Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin (Q33335679)

25 July 2017

1 reference

title

Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin (English)

1 reference

heparin-induced thrombocytopenia

25 July 2017

1 reference

1 reference

1 reference

N Lubenow

1

1 reference

25 July 2017

A Greinacher

series ordinal

2

1 reference

25 July 2017

publication date

1 November 2000

1 reference

Journal of Thrombosis and Thrombolysis

25 July 2017

published in

1 reference

25 July 2017

volume

10 Suppl 1

1 reference

25 July 2017

page(s)

47-57

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1027333320023

25 July 2017

exact match

0 references

cites work

Pregnancy complicated by heparin associated thrombocytopenia: management by a prospectively in vitro selected heparinoid (Org 10172).

1 reference

12 December 2020

Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor

1 reference

12 December 2020

Recombinant hirudin: clinical pharmacology and potential applications in nephrology

1 reference

12 December 2020

Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia

1 reference

12 December 2020

Dermatan sulphate in heparin-induced thrombocytopenia

1 reference

12 December 2020

A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open heart surgery

1 reference

12 December 2020

Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172)

1 reference

12 December 2020

Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance

1 reference

12 December 2020

Failure of current strategies in the prevention of thrombosis in patients with heparin-induced thrombocytopenia: a clinician's perspective

1 reference

12 December 2020

Thrombosis during the use of the heparinoid Organon 10172 in a patient with heparin-induced thrombocytopenia

1 reference

12 December 2020

Prothrombin activation induced by ecarin - A prothrombin converting enzyme from echis carinatus venom

1 reference

12 December 2020

Heparin-induced thrombocytopenia as the cause of persistent bleeding after pacemaker implantation

1 reference

12 December 2020

Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.

1 reference

12 December 2020

Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia

1 reference

12 December 2020

Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient

1 reference

12 December 2020

Limitations of conventional treatment options for heparin-induced thrombocytopenia

1 reference

12 December 2020

Orgaran (Org 10172): its pharmacological profile in experimental models

1 reference

12 December 2020

Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment.

1 reference

12 December 2020

Potentials risks in drug prevention of thrombosis--low-molecular-weight heparin versus standard heparin

1 reference

12 December 2020

Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.

1 reference

12 December 2020

Atypical heparin-induced thrombocytopenia complicated by intracardiac thrombus, effectively treated with ultra-low-dose rt-PA lysis and recombinant hirudin (Lepirudin).

1 reference

12 December 2020

Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.

1 reference

12 December 2020

Development of hirudin as an antithrombotic agent

1 reference

12 December 2020

cDNA cloning and deduced amino acid sequence of prothrombin activator (ecarin) from Kenyan Echis carinatus venom

1 reference

12 December 2020

Successful thrombolysis of right atrial and ventricle thrombi encircling a temporary pacemaker lead in a patient with heparin-induced thrombocytopenia type II.

1 reference

12 December 2020

Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome

1 reference

12 December 2020

Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid

1 reference

12 December 2020

Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.

1 reference

12 December 2020

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

12 December 2020

Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis.

1 reference

12 December 2020

The development of hirudin as an antithrombotic drug

1 reference

12 December 2020

New treatment options for heparin-induced thrombocytopenia.

1 reference

12 December 2020

Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time.

1 reference

12 December 2020

The anticoagulant effect of heparinoid Org 10172 during haemodialysis: an objective assessment

1 reference

12 December 2020

Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia.

1 reference

12 December 2020

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

12 December 2020

Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group

1 reference

12 December 2020

Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors

1 reference

12 December 2020

Pharmacological survey of recombinant hirudin

1 reference

12 December 2020

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

1 reference

12 December 2020

Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters

1 reference

12 December 2020

Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study

1 reference

12 December 2020

Recombinant hirudin is a heparin alternative in cardiac surgery

1 reference

12 December 2020

Modulation of thrombin and heparin activities by fibrin

1 reference

12 December 2020

The effect of r-hirudin vs. heparin on blood-membrane interactions during hemodialysis

1 reference

12 December 2020

Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia.

1 reference

12 December 2020

Recombinant hirudin and front-loaded alteplase in acute myocardial infarction: final results of a pilot study. HIT-I (hirudin for the improvement of thrombolysis)

1 reference

12 December 2020

Mechanisms of alpha-thrombin and beta-thrombin-E formation: use of ecarin for isolation of meizothrombin 1

1 reference

12 December 2020

Quantitative determination of hirudin in blood and body fluids

1 reference

12 December 2020

The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia

1 reference

12 December 2020

Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. An evaluation of native blood and plasma assays

1 reference

12 December 2020

Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia.

1 reference

12 December 2020

Plasma P-selectin is increased in thrombotic consumptive platelet disorders.

1 reference

12 December 2020

Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.

1 reference

12 December 2020

Recombinant hirudin (HBW 023): biological data of ten patients with severe venous thrombo-embolism

1 reference

12 December 2020

Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers

1 reference

12 December 2020

A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery

1 reference

12 December 2020

Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin

1 reference

12 December 2020

Pharmacology of r-hirudin in renal impairment

1 reference

12 December 2020

Danaparoid in the prevention of thromboembolic complications

1 reference

12 December 2020

Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man

1 reference

12 December 2020

A 14-year study of heparin-induced thrombocytopenia

1 reference

12 December 2020

Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay

1 reference

12 December 2020

A comparison between the use of recombinant hirudin and heparin during hemodialysis

1 reference

12 December 2020

Binding of fibrin monomer and heparin to thrombin in a ternary complex alters the environment of the thrombin catalytic site, reduces affinity for hirudin, and inhibits cleavage of fibrinogen

1 reference

12 December 2020

The mechanism of activation of bovine prothrombin by an activator isolated from Echis carinatus venon and characterization of the new active intermediates

1 reference

12 December 2020

Heparin-induced thrombocytopenia with thromboembolic arterial occlusion treated with recombinant hirudin

1 reference

12 December 2020

Immune endothelial-cell injury in heparin-associated thrombocytopenia

1 reference

12 December 2020

Serologic evidence of heparin sensitization in cancer patients receiving heparin flushes of venous access devices

1 reference

12 December 2020

Treatment of heparin-induced thrombocytopenia

1 reference

12 December 2020

Frequency of "optimal anticoagulation" for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). ALKK Study Group

1 reference

12 December 2020

Anticoagulation in patients with heparin-induced thrombocytopenia type II.

1 reference

12 December 2020

Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin

1 reference

12 December 2020

Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium

1 reference

12 December 2020

The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin dependent thrombocytopenia and thrombosis

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1027333320023

1 reference

Dimensions Publication ID

25 July 2017

1004987407

0 references

1 reference